Figure 2

Longitudinal changes in AST/ALT ratio in castration-resistant prostate cancer patients classified based on survival. (A) Longitudinal changes in AST/ALT ratio during treatment course according to patient survival in the total cohort, and nmCRPC and mCRPC groups. During the follow-up period, the AST/ALT ratio did not show a significant longitudinal change after PC diagnosis in surviving patients, whereas it was increased after CRPC diagnosis in deceased patients. **p < 0.01, ***p < 0.001. (B) Comparison of AST/ALT ratio differences between live and deceased patients at each stage in the three cohorts. At the time of PC diagnosis, the AST/ALT ratio in the total cohort was significantly greater for deceased patients. After CRPC treatment, AST/ALT ratio was also significantly higher for deceased patients in each of the three cohorts. **p < 0.01.